Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
about
Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysisPhase II study of sorafenib in patients with relapsed or refractory lymphoma.Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesPhase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaLate relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic eraA phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.Emerging drugs for Hodgkin's lymphoma.Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Current status of prognostication in classical Hodgkin lymphoma.Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin eraBIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
P2860
Q26765151-F3740966-DBDE-466A-8835-424EF8CA4BB3Q33401136-120B4809-6499-424A-AE8F-D94F77F629A3Q33404875-916ED0B3-B8A4-4885-90FA-CCCF809322E1Q33420273-8B53C472-94D8-4AB9-92DF-F1A101CE1233Q33886267-0A892411-1348-415F-AB94-2E545DE62D1EQ34064220-AA010CEF-C539-44C5-9D61-7B1CD533A5FDQ34240314-7C9209ED-B369-4301-838F-E07018F7A4FDQ35705317-0CA3E9AF-2817-4A31-A688-DE97B8D8C037Q35717972-9A8E1791-61D9-472D-A01C-7C3B670C0C12Q35925674-98FD3D27-390E-421E-9649-508BB56B1E4CQ36371623-C0B1F215-E7CD-4DB5-9D20-AAF2AD0019F8Q37126593-2029EF9B-4FF3-4207-8B20-1E3C04CCE6F8Q37144910-8045E39D-2AAB-46A2-91AA-BFCDC3EB9239Q37388718-EFA1671A-12C3-460C-8F9F-A3B023131F87Q37530611-262F08AB-E2A2-4149-874E-40B39E122018Q37683355-3D1E80AD-F2CB-4FCB-84B9-8560CAEF0068Q37772513-71A99BB3-2216-4422-8764-390C0362EB5EQ38073207-C7605CD8-9A22-4BE4-8EAF-7A135C4633ECQ38164572-DB0FF019-B7C5-4A5E-B55C-41D8B6ED06BBQ38185063-1FC8CA2F-AD9C-477C-B96C-82BC41D23445Q38264356-17F89265-E43A-4A79-87A1-CF1596360188Q38368587-6849A598-43C2-457E-B33C-B138C5A0BDF5Q38466376-78187186-C927-4FA1-826B-2C9019C4AABDQ38557033-6A2C2D73-7074-4313-B58A-C69C9F597D19Q38684561-AAC7FBFC-8A61-49FB-A9A8-3200B70B2269Q38781590-D4671C1E-F7E8-4567-8FB6-094E06567E2EQ38912382-A196677F-A27A-401F-AD3C-1D96143E1945Q38951604-3E918791-6DC7-4DF0-914B-E0E005B6D890Q38992200-B24AC936-CED3-444F-B8C8-D3EF4F60CB78Q39021652-B9F52319-CFA5-40CC-A70E-ACADE264D7C8Q39195424-8181C295-42DD-422E-85B7-87758F17DC18Q39202496-AD8C2C20-AB45-4BD8-813A-DE3F4AABC426Q39294879-248F98A7-B8D4-4BAF-8378-65148A7DDF54Q40149586-FCFCCC23-7D5D-4672-B6C3-FA0D8D5FB14EQ44120728-D8EFAF6E-66F8-4EEA-BC49-AA4FB652390AQ44750052-723380BE-EEE2-430B-B169-AD5108F39D8DQ46698290-24887BC7-D244-40BC-9475-A4B933B8ED9BQ47130656-692CD6D7-8865-4EF0-B97A-A1D1150B84D1Q52676516-ACD02649-FC61-4C76-876F-D1EC8C171C58Q52779365-F1302F31-F6B3-4FAB-86F2-71810FCC06F0
P2860
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@ast
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@en
type
label
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@ast
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@en
prefLabel
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@ast
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@en
P2093
P2860
P1476
Outcomes for patients who fail ...... ry refractory Hodgkin lymphoma
@en
P2093
Alison J Moskowitz
Andrew D Zelenetz
Craig H Moskowitz
Hugo Castro-Malaspina
Jill Vanak
Joachim Yahalom
Miguel-Angel Perales
Tarun Kewalramani
Zhigang Zhang
P2860
P304
P356
10.1111/J.1365-2141.2009.07727.X
P407
P577
2009-05-12T00:00:00Z